Medical Care Technologies, Inc. (OTC Pink:MDCE) Announces Positive Progress from Advanced Internal Testing of MDCE Melanoma Scan Beta Platform
Medical Care Technologies reported that its MDCE Melanoma Scan Beta platform achieved performance metrics slightly above industry benchmarks during advanced internal testing. Industry benchmarks for AI skin lesion analysis typically range from 78-86% sensitivity and 75-88% specificity; the company's internal results validated its proprietary computer vision and imaging algorithms.
Key figures
- Industry sensitivity range
- 78-86%
- Industry specificity range
- 75-88%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.